Related Experiment Video
Updated: Oct 15, 2025
Limbal Approach-Subretinal Injection of Viral Vectors for Gene Therapy in Mice Retinal Pigment Epithelium
Published on: August 7, 2015
CasRx-mediated RNA targeting prevents choroidal neovascularization in a mouse model of age-related macular
Changyang Zhou1,2, Xinde Hu1,2, Cheng Tang1,2
1Institute of Neuroscience, State Key Laboratory of Neuroscience, Key Laboratory of Primate Neurobiology, CAS Center for Excellence in Brain Science and Intelligence Technology, Shanghai Research Center for Brain Science and Brain-Inspired Intelligence, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, China.
Abstract:
RNA-targeting CRISPR system Cas13 offers an efficient approach for manipulating RNA transcripts in vitro. In this perspective, we provide a proof-of-concept demonstration that Cas13-mediated Vegfa knockdown in vivo could prevent the development of laser-induced CNV in mouse model of Age-related macular degeneration.
Insights
The Cas13 gene-editing tool effectively reduced Vegfa levels in mice, preventing the development of wet age-related macular degeneration. This RNA-targeting system shows promise for treating the condition.
Area of Science:
- Molecular Biology
- Genetics
- Ophthalmology
Background:
- RNA-targeting CRISPR systems like Cas13 enable precise manipulation of RNA transcripts.
- Age-related macular degeneration (AMD) is a leading cause of vision loss.
- Current treatments for wet AMD have limitations.
Purpose of the Study:
- To demonstrate the in vivo efficacy of Cas13 for targeting messenger RNA (mRNA).
- To investigate the potential of Cas13-mediated Vegfa knockdown in a mouse model of wet AMD.
- To evaluate Cas13 as a therapeutic strategy for preventing choroidal neovascularization (CNV).
Main Methods:
- Utilized the Cas13 system for targeted knockdown of Vascular Endothelial Growth Factor A (Vegfa) mRNA in vivo.
- Induced choroidal neovascularization (CNV) using a laser photocoagulation model in mice.
- Assessed the effect of Vegfa knockdown on CNV development and progression.
Main Results:
- Cas13-mediated Vegfa knockdown was successfully achieved in vivo.
- The Vegfa knockdown significantly prevented the formation and development of laser-induced CNV.
- Demonstrated proof-of-concept for RNA-targeting CRISPR in a disease model.
Conclusions:
- Cas13 represents a viable tool for in vivo RNA manipulation.
- Targeting Vegfa with Cas13 offers a potential therapeutic approach for wet age-related macular degeneration.
- Further research into Cas13-based therapies for ocular diseases is warranted.
